Navigation Links
Amarin Announces Successful Completion of Offering of American Depositary Shares
Date:1/11/2011

MYSTIC, Conn. and DUBLIN, Jan. 11, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has completed its previously announced underwritten public offering of American Depositary Shares ("ADSs") at a price to the public of $7.60 per ADS.

Due to the exercise in full of the underwriters' over-allotment option, the company sold a total of 13,800,000 ADSs in the offering for an aggregate public offering amount of approximately $104.9 million, and received approximately $100.2 million of net proceeds from the offering, after deducting the underwriting discount and estimated expenses of the offering payable by the company.

Amarin anticipates using the net proceeds from the offering to prepare for the commercialization of AMR101, file a New Drug Application and for working capital and general corporate purposes.

Jefferies & Company, Inc. and Leerink Swann LLC acted as joint book-running managers for the offering and Canaccord Genuity Inc. acted as co-lead manager for the offering.

The securities described above were offered by Amarin pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on November 23, 2010. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement relating to these securities may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340, and at Prospectus_Department@Jefferies.com. This news release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.Investor Contact Information:John F. TheroPresident In U.S.: +1 (860) 572-4979investor.relations@amarincorp.comLee M. SternThe Trout GroupIn U.S.: +1 (646) 378-2922lstern@troutgroup.comMedia Contact Information: David Schull or Martina Schwarzkopf, Ph.D.Russo PartnersIn U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)+1 (347) 591-8785 (mobile)david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.comMark Swallow or David DibleCitigate Dewe RogersonIn U.K.: +44 (0)207 638 9571mark.swallow@citigatedr.co.uk
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin to Present at UBS Life Sciences Conference
4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
6. Amarin Prices Public Offering of American Depositary Shares
7. Amarin Announces Underwriters Exercise of Over-Allotment Option
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... their offering. ... research Dry eye Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are ... are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Feb. 23, 2017 The U.S. Food ... PhenoTest BC Kit, performed on the Pheno System. ... that cause bloodstream infections and provide information about ... to (antibiotic sensitivity). The test also reduces the ... important information, which can guide antibiotic treatment recommendations ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... The Smart Machine ... from Oxford University predict that 47 percent of all jobs in the United States ... “smart” and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now ... . Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic ... Cut Pro X. , With ProGlass Prism users are given the tools and ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):